Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Aptevo Therapeutics (APVO) Receivables - Other (2020 - 2022)

Aptevo Therapeutics (APVO) has disclosed Receivables - Other for 3 consecutive years, with $3.1 million as the latest value for Q1 2022.

  • Quarterly Receivables - Other rose 28.62% to $3.1 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Mar 2022, up 28.62% year-over-year, with the annual reading at $3.7 million for FY2021, 54.66% up from the prior year.
  • Receivables - Other hit $3.1 million in Q1 2022 for Aptevo Therapeutics, down from $3.7 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $3.7 million in Q4 2021 to a low of $288000.0 in Q2 2020.
  • Historically, Receivables - Other has averaged $2.4 million across 3 years, with a median of $2.8 million in 2021.
  • Biggest five-year swings in Receivables - Other: soared 979.86% in 2021 and later grew 28.62% in 2022.
  • Year by year, Receivables - Other stood at $2.4 million in 2020, then soared by 54.66% to $3.7 million in 2021, then decreased by 15.01% to $3.1 million in 2022.
  • Business Quant data shows Receivables - Other for APVO at $3.1 million in Q1 2022, $3.7 million in Q4 2021, and $3.1 million in Q3 2021.